Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing
Open accessAbstract
Over 30% of the world's population is infected with Mycobacterium tuberculosis (Mtb), yet only ∼5-10% will develop clinical disease. Despite considerable effort, researchers understand little about what distinguishes individuals whose infection progresses to active tuberculosis (TB) from those whose infection remains latent for decades. The variable course of disease is recapitulated in cynomolgus macaques infected with Mtb. Active disease occurs in ∼45% of infected macaques and is defined by clinical, microbiologic and immunologic signs, whereas the remaining infected animals are clinically asymptomatic. Here, we use individually marked Mtb isolates and quantitative measures of culturable and cumulative bacterial burden to show that most lung lesions are probably founded by a single bacterium and reach similar maximum burdens. Despite this observation, the fate of individual lesions varies substantially within the same host. Notably, in active disease, the host sterilizes some lesions even while others progress. Our data suggest that lesional heterogeneity arises, in part, through differential killing of bacteria after the onset of adaptive immunity. Thus, individual lesions follow diverse and overlapping trajectories, suggesting that critical responses occur at a lesional level to ultimately determine the clinical outcome of infection. Defining the local factors that dictate outcome will be useful in developing effective interventions to prevent active TB.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Human infections likely always include at least some M. tuberculosis cells that are in stasis.
“Human infections likely always include at least some M. tuberculosis cells that are in stasis2.”
From The mycobacterial cell envelope — a moving target (2020) · cites this paper as [2]
The paper's discussion of bacterial dynamics (section labeled Abstract; page unavailable) says that growth in macaque lesions is drastically slowed after an initial rapid phase. It does not establish that cells are in stasis, or that every human infection contains such cells. (LLM, conf=0.82)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 21 · Cited by 533
Research works printed but not linked: 20
- [1]Zumla A Raviglione M Hafner R von Reyn CF Tuberculosis N Engl J Med 2013 368 745 755 23425167
- [2]Lin PL Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model Infect Immun 2009 77 4631 4642 19620341 PMC2747916
- [3]Capuano SV 3rd Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection Infect Immun 2003 71 5831 5844 14500505 PMC201048
- [4]Barry CE 3rd The spectrum of latent tuberculosis: rethinking the biology and intervention strategies Nat Rev Microbiol 2009 7 845 855 19855401 PMC4144869
- [5]Lin PL Flynn JL Understanding latent tuberculosis: a moving target J Immunol 2010 185 15 22 20562268 PMC3311959
- [6]Kaplan G Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity Infection and immunity 2003 71 7099 7108 14638800 PMC308931
- [7]Via LE Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [(1)(8)F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography Antimicrob Agents Chemother 2012 56 4391 4402 22687508 PMC3421588
- [8]Davis JM Ramakrishnan L The role of the granuloma in expansion and dissemination of early tuberculous infection Cell 2009 136 37 49 19135887 PMC3134310
- [9]Canetti G The Tubercle Bacillus 1955 New York, NY Springer Publishing Co, Inc
- [10]Lin PL Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques Proc Natl Acad Sci U S A 2012 109 14188 14193 22826237 PMC3435210
- [11]Ford CB Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection Nat Genet 2011 43 482 486 21516081 PMC3101871
- [12]Lin PL Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model Arthritis Rheum 2010 62 340 350 20112395 PMC3047004
- [13]Munoz-Elias EJ Replication dynamics of Mycobacterium tuberculosis in chronically infected mice Infection and immunity 2005 73 546 551 15618194 PMC538940
- [14]Wallis RS Tuberculosis biomarkers discovery: developments, needs, and challenges Lancet Infect Dis 2013 13 362 372 23531389
- [15]Walzl G Ronacher K Hanekom W Scriba TJ Zumla A Immunological biomarkers of tuberculosis Nat Rev Immunol 2011 11 343 354 21475309
- [16]Lin PL Early events in Mycobacterium tuberculosis infection in cynomolgus macaques Infection and immunity 2006 74 3790 3803 16790751 PMC1489679
- [17]Lin PL Radiologic responses in cynomolgus macaques fro assessing tuberculosis chemotherapy regimens Submitted for publication 2013 PMC3754323 23796926
- [18]Kennedy HE Vandiviere HM Willis HS The effects of extended incubation on propagability of tubercle bacilli Am Rev Tuberc 1958 77 802 814 13533799
- [19]Vandiviere HM Loring WE Melvin I Willis S The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection Am J Med Sci 1956 232 30 37 passim 13326887
- [20]Keane J Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N Engl J Med 2001 345 1098 1104 11596589
- Authors
- Lin, P. L., Ford, C. B., Coleman, M. T., Myers, A. J., Gawande, R., Ioerger, T., Sacchettini, J., Fortune, S. M., & Flynn, J. L.
- Affiliations
- Children's Hospital of Pittsburgh (US)
- Broad Institute (US)
- University of Pittsburgh (US)
- Harvard University (US)
- Texas A&M University (US)
- Corresponding author
- Fortune, Sarah M
- Flynn, JoAnne L
- ORCID
- Venue
- Nature Medicine
- Published
- 2013-12-15
- Volume
- 20
- Issue
- 1
- Pages
- 75-79
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC3947310
- OpenAlex
- W2092448486
- Cited by
- 533
- References
- 21
- Citations by year
- 2026: 34 · 2025: 33 · 2024: 37 · 2023: 41 · 2022: 45 · 2021: 37 · 2020: 48 · 2019: 32 · 2018: 47 · 2017: 56 · 2016: 39 · 2015: 43 · 2014: 40 · 2013: 1
- FWCI
- 29.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- Howard Hughes Medical Institute
- Bill and Melinda Gates Foundation
- Welch Foundation
- National Institutes of Health (DP2OD001378, HL106804)
- National Heart, Lung, and Blood Institute (R01HL106804, R01HL110811, HL106804, HL110811)
- National Institute of Allergy and Infectious Diseases (U19AI076217, AI-094745, R01AI094745, AI076217, T32AI007638)
- Children's Hospital of Pittsburgh
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Health Sciences › Medicine › Surgery › Infectious Diseases and Tuberculosis
- Keywords
- Mycobacterium tuberculosis, tuberculosis, latent tuberculosis infection, active tuberculosis, bacterial killing, bacterial load, adaptive immunity, tuberculosis vaccine development, macaque model
- MeSH terms
- Animals, Granuloma, Isoniazid, Lung, Macaca fascicularis, Models, Biological, Mycobacterium tuberculosis, Population Dynamics, Tuberculosis, Disease Progression, Positron-Emission Tomography, Latent Tuberculosis, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review